je.st
news
MARIZEV (Omarigliptin), Mercks Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes, Approved in Japan
2015-09-28 13:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved MARIZEV (omarigliptin) 25 mg and 12.5 mg tablets, an oral, once-weekly DPP-4 inhibitor indicated for the treatment of adults with type 2 diabetes. Japan is the first country to have approved omarigliptin. Language: English Contact: Media Contacts:Pam Eisele, 267-305-3558orMichael Close, 310-617-1067orKristen Drake, 908-236-4223orInvestor Contacts:Justin Holko, 908-740-1879orTeri Loxam, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: in
type
japan
approved
Category:Biotechnology and Pharmaceuticals